IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11161819 B1

PDFFull Text
Date of Patent:
Nov. 02, 2021

Filed:

Jul. 22, 2020

Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Gregory L. Adams, Vincentown, NJ (US);

Jason M. Cox, East Windsor, NJ (US);

John S. Debenham, Scotch Plains, NJ (US);

Scott Edmondson, Clark, NJ (US);

Eric J. Gilbert, Scotch Plains, NJ (US);

Yan Guo, Westfield, NJ (US);

Yu Jiang, East Windsor, NJ (US);

Hubert Josien, Jersey City, NJ (US);

Hyunjin M. Kim, Livingston, NJ (US);

Ping Lan, Plainsboro, NJ (US);

Shouwu Miao, Edison, NJ (US);

Christopher W. Plummer, Hoboken, NJ (US);

Murali Rajagopalan, Edison, NJ (US);

Unmesh Shah, Neshanic Station, NJ (US);

Zhongxiang Sun, Princeton, NJ (US);

Quang T. Truong, Morganville, NJ (US);

Feroze Ujjainwalla, Hoboken, NJ (US);

Francisco Velazquez, Clinton, NJ (US);

Srikanth Venkatraman, Edison, NJ (US);

Takao Suzuki, Shanghai, CN;

Nengxue Wang, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Baerbel R. Brown

Catherine D. Fitch

Primary Examiner:

David K O'Dell

Int. Cl.
CPC ...
C07D 217/04 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 413/04 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 401/06 (2006.01); C07D 417/04 (2006.01); A61K 31/4725 (2006.01); C07D 417/06 (2006.01); C07D 217/22 (2006.01); A61K 45/06 (2006.01); A61K 31/472 (2006.01); A61K 9/48 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
C07D 217/04 (2013.01); A61K 9/4858 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 29/00 (2018.01); C07D 217/22 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07D 417/06 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Find Patent Forward Citations

Loading…